Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Eli Lilly is expanding the supply ... The company launched 7.5 mg and 10 mg vials of tirzepatide, sold under the brand name Zepbound, which typically cost $599 and $699, respectively.

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...